5-Amino-1MQ Dosage: Oral vs SubQ Milligram Ranges Explained
5-Amino-1MQ dosage explained: how oral vs subcutaneous milligram tables differ in community logs versus preclinical NNMT research. Educational only—not a protocol.
PeptIQ Team
Peptide Research & Education
PeptIQ app
Log your NAD+ protocol in PeptIQ
Turn this NAD+ guide into a living protocol — doses, vials, and history in one place.
# 5-Amino-1MQ Dosage: Oral vs SubQ Milligram Ranges Explained
> Note: PeptIQ is not a medical provider. 5-Amino-1MQ is a research compound, not a peptide in the clinical-peptide sense. This article is educational only.
The existing 5-Amino-1MQ stack guide covers NNMT inhibition and why people discuss it next to GLP-1 agonists and MOTS-c. Search still wants a dedicated 5 amino 1mq dosage page, including oral vs subQ.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule NNMT inhibitor in preclinical metabolic work. That is a different evidence class from a weekly incretin trial. Dose tables on forums should be read as community habit, not as a labeled schedule.
Evidence tier
Layer
Strength
Limit
Preclinical NNMT / 5-Amino-1MQ papers
Mechanism hypotheses in animals and cells
No consumer milligram label
Stack blogs and logs
Oral capsule versus reconstituted powder stories
Observational
In-app entries
What people record as mg and route
Not outcomes
Do not invent trial PMIDs for a compound that is still mostly preclinical. If a specific paper is not already in the PeptIQ citation corpus, omit it.
5-Amino-1MQ is not a typical lyophilized peptide workflow
Educational reconstitution math, if someone is holding a claimed powder, is the same generic formula as other research chemicals sold as cakes:
Concentration (mg/mL) = labeled mg ÷ diluent mL
That math does not make the powder 5-Amino-1MQ, and it does not make subcutaneous use a studied human route.
Research-reference ranges versus forum tables
Community tables often discuss daily milligram-scale oral amounts, sometimes split, sometimes stacked with a GLP-1 log or MOTS-c. Those numbers are not a starting-dose instruction. They are what dosage threads repeat.
PeptIQ users who log 5-Amino-1MQ more often record an oral daily field than an injection field. That is a logging observation.
What this page will not do
Convert a GLP-1 weekly milligram into a 5-Amino-1MQ oral milligram
Treat "visceral fat" marketing as a trial endpoint
Publish a buy or source list
Related reading: the 5-Amino-1MQ stack guide for mechanism, the MOTS-c dosage guide for the mitochondrial neighbor, and NAD+ reconstitution education for the NAD-pool conversation people attach to NNMT.
Frequently Asked Questions
Q: Is there an official 5-Amino-1MQ human dose?
A: No labeled consumer schedule. Preclinical NNMT work and community logs are different evidence tiers. Treat forum milligram tables as observational language, not a protocol.
Q: Oral or subcutaneous?
A: Community write-ups mention both. Oral capsules dominate convenience stories. SubQ habits often copy peptide-vial workflows even though 5-Amino-1MQ is not a typical lyophilized peptide product.
Q: Can I convert a retatrutide weekly dose into a 5-Amino-1MQ oral milligram?
A: No. Different mechanisms, different evidence classes. Do not map GLP-1 weekly milligrams onto NNMT-inhibitor forum tables.
Bottom line
5-Amino-1MQ dosage queries outrun the human literature. Oral versus subcutaneous is a community handling split, not a comparative trial. Figures on forums are not a protocol.